Follow-Up of Gestational Diabetes Mellitus in an Urban Safety Net Hospital: Missed Opportunities to Launch Preventive Care for Women

被引:30
作者
McCloskey, Lois [1 ]
Bernstein, Judith [1 ]
Winter, Michael [2 ]
Iverson, Ronald [3 ,4 ]
Lee-Parritz, Aviva [3 ,4 ]
机构
[1] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA
[2] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA
[4] Boston Med Ctr, Boston, MA USA
关键词
MENSTRUAL MIGRAINE; PREMENSTRUAL SYMPTOMS; ORAL-CONTRACEPTIVES; DOUBLE-BLIND; FROVATRIPTAN; TOLERABILITY;
D O I
10.1089/jwh.2013.4628
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Our study assessed the follow-up of gestational diabetes mellitus (GDM) in the postpartum period among a racially and ethnically diverse group of women receiving care in a major urban medical center. Methods: We conducted cross-sectional analysis of clinical and administrative data on women aged 18-44 years who gave birth at Boston Medical Center (BMC) between 2003 and 2009, had GDM, and used BMC for regular care. We calculated the rate of glucose testing by 70 days and by 180 days after delivery and used logistic regression to assess the predictors of testing. Results: By 6 months postpartum, only 23.4% of GDM-affected women received any kind of glucose test. Among these, over half had been completed by 10 weeks but only 29% were the recommended oral glucose tolerance test (OGTT). After accounting for sociodemographic and health service factors, women aged <= 35 years of age and women with a family practice provider were significantly less likely to be tested than their counterparts (odds ratio [OR] 0.51; 95% confidence interval [CI] 0.32, 0.83 and OR 0.36; 95% CI 0.19, 0.71 respectively). Women who attended a primary care visit within 180 days after birth had three times higher odds of being tested than those without such a visit (OR 3.10; 95% CI 1.97, 4.87). Conclusions: Despite widely disseminated clinical guidelines, postpartum glucose testing rates are exceedingly low, marking a critical missed opportunity to launch preventive care for women at high risk of type 2 DM. Failed follow-up of GDM by providers of prenatal and postpartum care also reflects a broader systems failure: the absence of a well-supported transition from pregnancy care to ongoing primary care for women.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 21 条
[1]   Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan [J].
Allais, Gianni ;
Bussone, Gennaro ;
Airola, Gisella ;
Borgogno, Paola ;
Gabellari, Ilaria Castagnoli ;
De Lorenzo, Cristina ;
Pavia, Elena ;
Benedetto, Chiara .
NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 1) :S186-S190
[2]   Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks [J].
Brandes, J. L. ;
Poole, A. C. ;
Kallela, M. ;
Schreiber, C. P. ;
MacGregor, E. A. ;
Silberstein, S. D. ;
Tobin, J. ;
Shaw, R. .
CEPHALALGIA, 2009, 29 (11) :1133-1148
[3]   The influence of estrogen on migraine - A systematic review [J].
Brandes, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (15) :1824-1830
[4]   Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives [J].
Coffee, Andrea L. ;
Kuehl, Thomas J. ;
Sulak, Patricia J. .
PHARMACOTHERAPY, 2008, 28 (05) :576-583
[5]   Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen [J].
Coffee, Andrea L. ;
Sulak, Patricia J. ;
Kuehl, Thomas J. .
CONTRACEPTION, 2007, 75 (06) :444-449
[6]   Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen [J].
Coffee, Andrea L. ;
Kuehl, Thomas J. ;
Willis, Sherilyn ;
Sulak, Patricia J. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 195 (05) :1311-1319
[7]   Migraine headache recurrence:: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans [J].
Géraud, G ;
Keywood, C ;
Senard, JM .
HEADACHE, 2003, 43 (04) :376-388
[8]   Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine [J].
Guidotti M. ;
Mauri M. ;
Barrilà C. ;
Guidotti F. ;
Belloni C. .
The Journal of Headache and Pain, 2007, 8 (5) :283-288
[9]  
Hatcher RA, 2007, CONTRACEPTIVE TECHNO, P477
[10]   Migraine prevalence, disease burden, and the need for preventive therapy [J].
Lipton, R. B. ;
Bigal, M. E. ;
Diamond, M. ;
Freitag, F. ;
Reed, M. L. ;
Stewart, W. F. .
NEUROLOGY, 2007, 68 (05) :343-349